Benzimidazole and Benzimidazolone Based PROTAC Compounds for LRRK2 Degradation

The USPTO issued patent grant US12589156B2 to Arvinas Operations, Inc. for compounds of Formula (Ia) that function as PROTAC molecules targeting leucine-rich repeat kinase 2 (LRRK2) for proteasomal degradation. The patent, classified under A61P 25/28 (nervous system diseases), includes 12 claims covering the benzimidazole and benzimidazolone-based compound structures.

This is a routine patent grant providing intellectual property protection to the patent holder. There are no compliance requirements or deadlines for third parties. Competitors developing similar PROTAC therapeutics targeting LRRK2 should review this patent to understand potential freedom-to-operate considerations and may need to design around the granted claims.